-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Suspected patent abuse hinders competition, and Novartis is once again caught in the whirlpool
.
Recently, the Swiss Competition Commission (COMCO) said it had launched an investigation into
a pharmaceutical company that "may have illegally used patents to hinder competition".
Novartis Corporation Statement
Novartis Corporation Statement
▲The screenshot is from the official website of Novartis
Specifically, COMCO said there was news that the pharmaceutical company was trying to initiate litigation by using a patent to protect its drugs for skin diseases from competing products
.
In response to the investigation, representatives of COMCO raided Novartis' corporate headquarters
in Basel.
In response, Novartis said that the opening of the investigation does not mean that any misconduct or any financial impact is found, and it is fully cooperating with the authorities and is confident of clarifying the legitimacy
of its position.
In recent years, Novartis has ranked among the best
in global sales and net profit.
Novartis sells TOP20 products
Novartis sells TOP20 products
Source: Novartis 2022 semi-annual report
According to Novartis' product line, its best-performing dermatological treatment is Cosentyx (scuchiyumab
).
More notably, Cosentyx is one of
the most critical drugs driving Novartis' growth.
In fact, since Cosentyx was launched in 2015, as the first new generation of psoriasis treatment drugs in the United States, it has become a blockbuster
.
In addition to numerous biosimilar challenges, the drug's direct competitors are Eli Lilly Taltz (izumab), Johnson & Johnson Tremfya (gussetschulumab), AbbVie Skyrizi (risankizumab
).
According to Novartis' annual report, Cosentyx's psoriasis use patent is expected to expire in the United States in 2032 and in the European Union in 2031
.
This is not the first time Novartis has been involved in a similar issue
.
Coincidentally, another Novartis product, Entresto, has also been repeatedly challenged for patents, with various patents due in the United States due
in 2036.
Along the way, Novartis has wandered between patent litigation and being sued
.
Source:
